BioPharma Resources

Drug Trial Radar · NCT01633853

Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder

Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease

Last checked: Nov 19, 2026Latest source record: Feb 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

204

Actual

Start

Jul 2012

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Dongliang Zhang, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Municipal Science & Technology Commission
First posted
Jul 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is hypothesised that the efficacy and safety of Vitamin D2 soft capsule to treat the Chronic Kidney Disease Mineral and Bone Disease (CKD-MBD) are equal to 1,25(OH)2 Vitamin D3 (Rocaltrol) in the patients with CKD stage 3-5.

Conditions

  • Vitamin D Deficiency

Interventions

  • Vitamin D2Drug

    Treatment with Vit D2.

  • 1,25(OH)2 Vit D3Drug

    Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Blood Levels of Calcium at the 24th Month of Following up.Time frame: 24 months
  2. The Blood Levels of Phosphorus at the 24th Month of Following up.Time frame: 24 months
  3. The Blood Levels of Intact Parathyroid Hormone at the 24th Month of Following up.Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friedship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.